Shukla Sath 4
4 · Spero Therapeutics, Inc. · Filed Feb 3, 2023
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Award
Common Stock
2023-02-01+265,957→ 322,021 total - Sale
Common Stock
2023-02-02$1.83/sh−9,504$17,372→ 312,517 total
Footnotes (4)
- [F1]Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
- [F2]Includes 312,518 RSUs held by the Reporting Person.
- [F3]The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting of RSUs that were granted to the Reporting Person on February 1, 2022.
- [F4]Represents the weighted average sales price per share. The shares sold at prices ranging from $1.81 to $1.86 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.